In vitro potentiation of antimalarial activities by daphnetin derivatives against Plasmodium falciparum

Biomedical and Environmental Sciences

Volumn 19, Issue 5, 2006, Pages 367-370

  Huang, Fang ^a   Tang, Lin Hua ^a   Yu, Lin Qian ^b   Ni, Yi Chang ^a   Wang, Qin Mei ^a   Nan, Fa Jun ^b  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Antimalarial; Daphnetin; Drug screening

Indexed keywords

ANTIMALARIAL AGENT; DAPHNETIN; UMBELLIFERONE DERIVATIVE;

ANIMAL; ARTICLE; CHEMISTRY; DRUG EFFECT; PLASMODIUM FALCIPARUM;

ANIMALS; ANTIMALARIALS; PLASMODIUM FALCIPARUM; UMBELLIFERONES;

PLASMODIUM FALCIPARUM;

EID: 33845497163     PISSN: 08953988     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Greenwood B, Mutabingwa T (2002). Malaria in 2002. Nature 415, 670-672.
2. Mabeza G F, Loyevsky M, Gordeuk V R, et al. (1999). Iron chelation therapy for malaria: a review. Pharmacol Ther 81, 53-57.
3. Yang Y Z, Ranz A, Pan H Z, et al. (1992). Daphnetin: a novel antimalarial agent with in vitro and in vivo activity. Am J Trop Med Hyg 46, 15-20.
4. Wang Q M, Ni Y C, Xu Y Q, et al. (2000). The schizontocidal activity of Daphnetin against malaria parasites in vitro and in vivo. Chin J Parasitol Parasit Dis 18, 204-206.
5. Mu L Y, Wang G M, Ni Y C (2002). In vitro antimalarial effect of Daphnetin relating to its iron-chelating activity. Chin J Parasitol Parasit Dis 20, 83-85.
6. Yolanda C, Liuris H, Jose G, et al. (2004). A novel DNA-based microflurimetric method to evaluate antimalarial drug activity. Am J Trop Med Hyg 70 (2), 119-124.
7. Trager W, Jensen J B (1976). Human malaria parasites in contimuous culture. Science 193, 673-675.
8. Lytton S D, Mester B, Dayan I, et al. (1993). Mode of action of iron (III) chelators as antimalarials: I. Membrane permeation properties and cytotoxic activity. Blood 81, 214-221.
9. Ingram G M, Kinnaird J H (1999). Ribonucleotide Reductase: a new target for antiparasite therapies. Parasitology Today 15, 338-342.
10. Rubin H, Salem J S, Li L S, et al. (1993). Cloning, sequence determination, and regulation of the Ribonucleotide Reductase subunits from Plasmodium falciparum: a target for antimalarial therapy. Proc Natl Acad Sci 90, 9280-9284.
11. Loyevsky M, John C, Dickens B, et al. (1999). Chelation of iron within the erythrocytic Plasmodium falciparum parasite by iron chelators. Mol Biochem Parasitol 101, 43-59.
12. Cabantchik Z I, Glickstein H, Golenser J, et al. (1996). Iron chelators: mode of action as antimalarials. Acta Haematol 95, 70-77.
13. Yang E B, Zhao Y N, Zhang K, et al. (1999). Daphnetin, one of coumarin derivatives, is a protein kinase inhibitor. Biochem Biophys Res Commun 260 (3), 682-685.
14. Scheibel L W, Rodriguez S (1989). Anti-malarial activity of selected aromatic chelators. V. Localization of 59Fe in Plasmodium falciparum in the presence of oxines. Prog Clin Biol Res 313, 119-149.
15. Hider R C (2002). Design of therapeutic chelating agents. Biochemical Society Transactions 30, 751-754.
16. Liu J, Tian J, Li Y, et al. (2004). Binding of the bioactive component daphnetin to human serum albumin demonstrated using tryptophan fluorescence quenching. Macromol Biosci 17, 520-525.
17. Nicolaus V W, Hicham K, Hider R C (2000). Hydroxylated Phytosiderophore Species Possess an Enhanced Chelate Stability and Affinity for Iron (III). Plant Physiol 124 (3), 1149-1158.
18. 3+ values of iron(III) ligands with clinical potential. Metal Ions in Biology and Medicine 5, 51-55.
19. Garrett T M, Miller P W, Raymond K N (1989). 2, 3- Dihydroxyteraphthalamides: highly efficient iron (III) chelating agents. Inorg Chem 28, 128-133.